Loading stock data…
$11.84-0.17 (-1.46%)
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States.
Avalo Therapeutics, Inc. in the Healthcare sector is trading at $12.07 with a market capitalization of $1.0B. Wall Street consensus targets $44.08 (12 analysts), implying a +265.1% move over the next 12 months. The stock is currently near its 52-week low of $11.72, remaining 26.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 16 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $59,000 | $0 | $0 |
| Gross Profit | — | — | $59,000 | $0 | $0 |
| Operating Income | -$31.52M↓ | -$20.90M↓ | -$19.74M↓ | -$19.20M↑ | -$19.32M |
| Net Income | -$36.36M↓ | -$19.63M↓ | -$13.72M↑ | -$30.63M↓ | -$20.77M |
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interl...